LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 97 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $487,025 | -15.6% | 412,733 | +0.8% | 0.00% | – |
| Q2 2023 | $577,071 | +41.2% | 409,270 | +50.2% | 0.00% | – |
| Q1 2023 | $408,645 | +138.8% | 272,430 | +86.3% | 0.00% | – |
| Q4 2022 | $171,096 | +23.1% | 146,236 | +19.1% | 0.00% | – |
| Q3 2022 | $139,000 | +152.7% | 122,796 | +255.5% | 0.00% | – |
| Q2 2022 | $55,000 | -63.3% | 34,542 | -64.4% | 0.00% | – |
| Q1 2022 | $150,000 | -79.9% | 97,003 | -68.2% | 0.00% | – |
| Q4 2021 | $746,000 | +74.3% | 304,794 | +79.2% | 0.00% | – |
| Q3 2021 | $428,000 | +4.6% | 170,056 | +18.6% | 0.00% | – |
| Q2 2021 | $409,000 | -38.2% | 143,404 | -49.0% | 0.00% | – |
| Q1 2021 | $662,000 | +771.1% | 281,418 | +560.7% | 0.00% | – |
| Q4 2020 | $76,000 | -31.5% | 42,596 | -66.4% | 0.00% | – |
| Q2 2020 | $111,000 | +68.2% | 126,730 | +57.6% | 0.00% | – |
| Q1 2020 | $66,000 | -22.4% | 80,437 | -15.3% | 0.00% | – |
| Q4 2019 | $85,000 | +117.9% | 94,980 | +141.1% | 0.00% | – |
| Q3 2019 | $39,000 | – | 39,391 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,935,485 | $41,223,872 | 3.66% |
| Raffles Associates | 1,587,739 | $1,873,532 | 2.48% |
| Defender Capital, LLC. | 5,184,510 | $6,117,722 | 2.22% |
| Prescott General Partners LLC | 1,851,851 | $2,185,184 | 0.14% |
| DCF Advisers, LLC | 82,751 | $97,646 | 0.05% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $63,450 | 0.05% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 781,766 | $922,484 | 0.02% |
| Fort Sheridan Advisors LLC | 83,931 | $99,039 | 0.02% |
| MAI Capital Management | 954,688 | $1,126,532 | 0.02% |
| Piscataqua Savings Bank | 12,499 | $14,623 | 0.01% |